Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Outpatient management after salvage chemotherapy for relapsed or refractory malignant lymphoma with pegfilgrastim support
jRCTs071180008Completed
- Sponsor
- Kyowa Kirin
- Start
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of pegfilgrastim in lymphosarcoma, non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL), sponsored by Kyowa Kirin. Primary endpoint: Ratio of outpatient management period (days). Started Jul 2017; status: completed.
02
Drugs
pegfilgrastim
03
Conditions
lymphosarcomanon-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on jRCTs071180008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071180008.